January 7, 2026 — Leads & Copy — Genmab A/S (Nasdaq: GMAB) has partnered with Anthropic to advance the company’s research and development (R&D) processes through the adoption of artificial intelligence (AI) capabilities.
Genmab and Anthropic will design and deploy custom, Claude-powered agentic AI solutions to support Genmab’s clinical development priorities. Genmab’s teams will use Claude to accelerate data processing, analysis, and document generation within defined guardrails and with human oversight to streamline complex operational activities, enhance agility, and improve consistency in supporting Genmab’s clinical programs as they progress toward key regulatory milestones.
Tahamtan Ahmadi, M.D., Ph.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines, Genmab, said the partnership represents a step forward in Genmab’s transformation toward a more scalable, efficient, and digitally enabled R&D engine aligned with the company’s AI strategy. Ahmadi added that by reducing manual burden and enabling greater scale across Genmab’s operations, the partnership with Anthropic will empower teams to focus more time on high-value scientific and strategic work, with the goal of accelerating the path to patient impact.
Genmab continues to advance several late-stage investigational antibody medicines across solid tumors and hematological malignancies and is investing in digital and AI-driven capabilities that will further support the expansion and execution of its growing pipeline.
Kate Jensen, Head of Americas at Anthropic, said clinical development is critical, heavily regulated, and directly tied to patient outcomes. Jensen added that is why they are partnering with an biotech company like Genmab as they apply AI to support their clinical development process and are working with Genmab to deploy Claude and build custom agentic solutions with the intention to help their team focus on the hard problems that require human expertise and get therapies to patients faster.
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. The company has advanced a range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a late-stage clinical pipeline, including wholly owned programs, with the goal of delivering medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific.
Contact:
For more information, please visit Genmab.com and follow us on LinkedIn and X.
Source: Genmab
